Teva Pharmaceutical Industries (NYSE:TEVA) Q4 results:
Revenues:$4,468M (+1%); North America: $2,373M (+6%); Generics: $2,497M (+2%), Copaxone: $387M (-22%).
Net income: $110M (+104%); non-GAAP net income: $683M (+26%); EPS: ($0.91); non-GAAP EPS: $0.10 (+104%).
Consensus was non-GAAP EPS of $0.61 on revenues of $4.35B.
Cash flow ops (full year): $748M (-69%). Decrease mainly due to the working capital adjustment with Allergan and the Rimsa settlement in 2018 and lower profits in North America in 2019.
Cash flow ops in Q4: $538M (+47%).
All components of 2019 outlook met, including spend base reduction target of $3B.
2020 guidance: Revenues: $16.6B - 17.0B; Copaxone sales: ~$1.2B; Austedo sales: ~$650M; AJOVY sales: ~$250M; non-GAAP EPS: $2.30 - 2.55; free cash flow: $1.8B - 2.2B.
Source Seeking ALPHA
Revenues:$4,468M (+1%); North America: $2,373M (+6%); Generics: $2,497M (+2%), Copaxone: $387M (-22%).
Net income: $110M (+104%); non-GAAP net income: $683M (+26%); EPS: ($0.91); non-GAAP EPS: $0.10 (+104%).
Consensus was non-GAAP EPS of $0.61 on revenues of $4.35B.
Cash flow ops (full year): $748M (-69%). Decrease mainly due to the working capital adjustment with Allergan and the Rimsa settlement in 2018 and lower profits in North America in 2019.
Cash flow ops in Q4: $538M (+47%).
All components of 2019 outlook met, including spend base reduction target of $3B.
2020 guidance: Revenues: $16.6B - 17.0B; Copaxone sales: ~$1.2B; Austedo sales: ~$650M; AJOVY sales: ~$250M; non-GAAP EPS: $2.30 - 2.55; free cash flow: $1.8B - 2.2B.
Source Seeking ALPHA